Carolinas Wealth Consulting’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-24
Closed -$1.47K – 1062
2023
Q2
$1.43K Hold
24
– – ﹤0.01% 858
2023
Q1
$1.4K Hold
24
– – ﹤0.01% 851
2022
Q4
$1.49K Hold
24
– – ﹤0.01% 844
2022
Q3
$1K Hold
24
– – ﹤0.01% 827
2022
Q2
$2K Hold
24
– – ﹤0.01% 764
2022
Q1
$2K Hold
24
– – ﹤0.01% 798
2021
Q4
$2K Hold
24
– – ﹤0.01% 831
2021
Q3
$1K Hold
24
– – ﹤0.01% 869
2021
Q2
$1K Hold
24
– – ﹤0.01% 881
2021
Q1
$1K Buy
+24
New +$1.45K ﹤0.01% 879

Other funds holding IHE

Carolinas Wealth Consulting's IHE Position: Q3 2023 in Review

Carolinas Wealth Consulting sold out of iShares US Pharmaceuticals ETF (IHE) in Q3 2023, closing a stake of 24 shares — an estimated $1.47K sold.

Carolinas Wealth Consulting first reported a position in IHE in Q1 2021 and held it in 10 quarters. The position peaked at $2K in Q2 2022. 128 funds tracked by Wall St. Rank hold IHE as of Q3 2023.

  • Carolinas Wealth Consulting reported no remaining iShares US Pharmaceuticals ETF position as of Q3 2023 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 24 iShares US Pharmaceuticals ETF shares in Q3 2023, an estimated $1.47K.
  • Carolinas Wealth Consulting first reported a position in iShares US Pharmaceuticals ETF in Q1 2021 and held it in 10 quarters.
  • Carolinas Wealth Consulting's iShares US Pharmaceuticals ETF position peaked at $2K in Q2 2022.
  • 128 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q3 2023.

Based on Carolinas Wealth Consulting's 13F filing for Q3 2023, filed 14 Nov 2023.